FOLH1 and prostate adenocarcinoma: Two PSMA-expressing prostate cancer cell lines were chosen for the initial studies: (1) LNCaP cells, derived from human prostate adenocarcinoma cells; and (2) transgenic adenocarcinoma mouse prostate (TRAMP)-C2 cells derived from a heterogeneous 32-week tumor grown in the TRAMP mouse model.